Two-Drug HIV pill shows promise for teens, reducing Long-Term side effects
NCT ID NCT03682848
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tested a two-drug HIV pill (dolutegravir/lamivudine) in 32 teens aged 12-18 who had never taken HIV medication before. The goal was to see if this simpler daily pill could control the virus as well as standard three-drug regimens, while lowering the risk of long-term side effects. After 48 weeks, the study measured how many teens had undetectable virus levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Kericho, 20200, Kenya
-
GSK Investigational Site
Kisumu, 40100, Kenya
-
GSK Investigational Site
Cape Town, 7500, South Africa
-
GSK Investigational Site
Durban, 4001, South Africa
-
GSK Investigational Site
Johannesburg, 1862, South Africa
-
GSK Investigational Site
Bangkok, 10330, Thailand
-
GSK Investigational Site
Bangkok, 10700, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand
Conditions
Explore the condition pages connected to this study.